MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
PARP inhibition in cancer therapy
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,206 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,206 works in the cohort · of 4,299,418page 16 of 25

Labels cover 6 of 1,206 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,206 of 1,206 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Cancer Prognosis According to Parthanatos Features
Alessandra Messikommer, Bruktawit Maru, Katja Seipel, Peter J.M. Valk, Alexandre Theocharides, Thomas Pabst +2 more
2021· preprint· en· bioRxiv (Cold Spring Harbor Laboratory)· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial
Christian Marth, Tjoung‐Won Park‐Simon, Carol Aghajanian, Alexander Reuß, Shin Nishio, Myong Cheol Lim +14 more
2023· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
Carol Aghajanian, Barbara Schmalfeldt, Aikou Okamoto, JW Kim, G. Marquina Ospina, Ali̇ Ayhan +13 more
2024· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A
Jonathan W. Riess, Jieling Miao, Paul Wheatley‐Price, Karen L. Reckamp, David Kozono, M.W. Redman +14 more
2024· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations

How this was built: Screen · Findings · About